Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer (Q37766575)

22 August 2017

Economic evaluation of erythropoiesis-stimulating agents for anemia related to cancer (English)

1 reference

22 August 2017

Natasha Wiebe

7

0 references

Marcello Tonelli

object named as

Marcello Tonelli

9

0 references

author name string

Scott Klarenbach

1

1 reference

22 August 2017

Braden Manns

2

1 reference

22 August 2017

Tony Reiman

3

1 reference

22 August 2017

Martin Neil Reaume

4

1 reference

22 August 2017

Helen Lee

5

1 reference

22 August 2017

Anita Lloyd

6

1 reference

22 August 2017

Brenda Hemmelgarn

8

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

22 August 2017

1 reference

22 August 2017

116

1 reference

22 August 2017

13

1 reference

22 August 2017

3224-3232

1 reference

A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment

22 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

Risks associated with transfusion of cellular blood components in canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Randomized multicentre trial of the influence of recombinant human erythropoietin on intraoperative and postoperative transfusion need in anaemic patients undergoing right hemicolectomy for carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Treating anemia of cancer with every-4-week darbepoetin alfa: final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Erythropoietin for anaemia in cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Perioperative erythropoietin administration in patients with gastrointestinal tract cancer: prospective randomized double-blind study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Impact of epoetin beta on quality of life in patients with malignant disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

National Institute for Clinical Excellence and its value judgments

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Modeling valuations for EuroQol health states

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

A study of the quality of life and cost-utility of renal transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25052

7 January 2021

Identifiers

DOI

10.1002/CNCR.25052

1 reference

22 August 2017

1 reference